Navigation Links
SyntheMed Files Universal Shelf Registration
Date:11/7/2007

ISELIN, N.J., Nov. 7 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, tissue repair and drug delivery products, announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow SyntheMed to sell, from time to time, up to $20 million of its common stock, debt securities, preferred stock, warrants to purchase common stock, preferred stock or debt securities, or any combination thereof from time to time in one or more offerings. The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement that SyntheMed will file with the SEC.

SyntheMed expects to use the net proceeds from any sale of securities under this registration statement for general corporate purposes including expenses associated with the anticipated US market launch of REPEL-CV(R) Adhesion Barrier, research and development expenses for new product opportunities including potential applications of its polymer film technology in spine and ENT surgery and costs related to post-approval clinical trials for REPEL-CV.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers or orders to buy the securities be accepted prior to the time the registration statement becomes effective. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers, solicitations of offers to buy or sales of securities will only be made pursuant to the registration statement filed with and declared effective by the SE
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. SyntheMed to Present at the Acumen BioFin Conference
3. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. Arrow International Files and Mails Definitive Proxy Materials
7. VaxGen Files 2006 Financial Statements and Provides Cash Update
8. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
9. Anacor Files Registration Statement for Initial Public Offering
10. IsoTis Files Definitive Proxy Statement
11. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 In preparation for VARTECH 2014, ... cybersecurity company focused on authentication and SSO announced today ... ability to generate a OTP through the presentation of ... of user-based RFID authentication, 2FA,s solutions have leveraged the ... many years. RFID authentication is broadly deployed in healthcare ...
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... solid, liquid, and gasbut much stranger things ... phase transitions occur at the coldest temperatures ... can dramatically transform a material. , ... Brookhaven National Laboratory and Stony Brook University ... zero to isolate and probe these quantum ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
Breaking Biology Technology:2FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) a ... to bio-pharmaceutical and healthcare organizations and the market leader ... drug development, announced today that its Board of Directors ... and Chief Executive Officer and as a member of ...
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... for the first quarter ended March 31, 2011. ... cash equivalents and investment securities of $23.1 million, as ...
... 2011 Frost & Sullivan Europe New Product Innovation Award ... for its state-of-the-art, high precision Novelda Impulse Radar transceiver ... Radar transceiver is a cutting-edge radar transceiver that incorporates ... unique penetration capabilities," remarks Frost & Sullivan Research Analyst ...
Cached Biology Technology:ERT Announces Appointment of New President and CEO 2ERT Announces Appointment of New President and CEO 3ERT Announces Appointment of New President and CEO 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results 4Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 2Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 3Frost & Sullivan Award Acknowledges Novelda's Cutting-Edge Product Innovation 4
(Date:9/16/2014)... PALM BEACH GARDENS, Fla. , Sept. 16, ... provider of biometric identity management solutions, announced today ... handheld solution designed to authenticate the identity of ... The Android-based Verifier Sentry rapidly reads ... the credential holder,s ID by matching the biometric ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Smithsonian scientists discover tropical tree microbiome in Panama 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... go through a laboratory version of boot camp may ... of Pittsburgh researchers. In essence, that's the concept behind ... a patient's own souped up dendritic cells, which have ... system in fighting the virus unique to that individual. ...
... affiliate of Harvard Medical School, are the first to ... angiogenesis (new blood vessel growth). The switch, they learned, ... two enzymes (known as PI3K and PLCg) that compete ... fulfill opposite missions, growth and regression, respectively. This finding ...
... at the Harvard Department of Ophthalmology's Schepens Eye Research ... the first to learn why the cornea, the clear ... unique phenomenon that makes vision possible. The key, say ... of the protein VEGFR-3 (vascular endothelial growth factor receptor-3) ...
Cached Biology News:T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 2Schepens scientists are first to discover angiogenesis switch inside blood vessel cells 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... of large numbers of samples may be carried ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
Biology Products: